Results 51 to 60 of about 983 (198)

Enantioseparation of solriamfetol and its major impurity phenylalaninol by capillary electrophoresis using sulfated gamma cyclodextrin [PDF]

, 2021
R-solriamfetol is a recently approved drug used for the treatment of excessive sleepiness associated with narcolepsy and sleep apnea. Herein, a capillary electrophoretic method was developed, enabling the simultaneous analysis of the API and its S ...
Béni, Szabolcs, Fejős, Ida, Köteles, István, Malanga, Milo, Szabó, Zoltán István, Tóth, Gergő, Várnai, Bianka   +6 more
core   +3 more sources

Solriamfetol for the Use of Narcolepsy: A Systematic Review

Cureus, 2022
Narcolepsy is a chronic and disabling neurological disorder characterized by excessive daytime sleepiness (EDS) and cataplexy. Historically, some medications have demonstrated efficacy in managing EDS and cataplexy symptoms. However, some patients cannot tolerate them, become refractory, or may use concomitant medications that preclude the use due to ...
Iturburu, Alisson, Pallares Vela, Elisa, Cruz, Claudio, Yepez, Mario, Ortiz, Juan Fernando, Krishna, Krithika, Peña, Gabriela, Cordova, Steven, Khurana, Mahika, Bandarupalli, Pranathi   +9 more
openaire   +2 more sources

The orexin story and orexin receptor antagonists for the treatment of insomnia

Journal of Sleep Research, Volume 32, Issue 6, December 2023., 2023
Summary Insomnia is present in up to one third of the adult population worldwide, and it can present independently or with other medical conditions such as mental, metabolic, or cardiovascular diseases, which highlights the importance of treating this multifaceted disorder.
Clemens Muehlan, Catherine Roch, Cedric Vaillant, Jasper Dingemanse   +3 more
wiley   +1 more source

Solriamfetol Titration & AdministRaTion (START) in Patients With Narcolepsy

Clinical Therapeutics, 2022
Solriamfetol, a dopamine/norepinephrine reuptake inhibitor, is approved (in the United States and European Union) to treat excessive daytime sleepiness (EDS) in adults with narcolepsy (75-150 mg/d) or obstructive sleep apnea (OSA) (37.5-150 mg/d). This study characterized real-world titration strategies for patients with narcolepsy (with or without ...
Michael J, Thorpy, Danielle, Hyman, Gregory S, Parks, Abby, Chen, Catherine, Foley, Beth, Baldys, Diane, Ito, Haramandeep, Singh   +7 more
openaire   +2 more sources

Retrospective cohort study of hypersomnias of central origin from two Australian tertiary sleep disorders services

Internal Medicine Journal, Volume 53, Issue 10, Page 1783-1789, October 2023., 2023
Abstract Background Hypersomnias of central origin (HOCO) are diverse in origin and symptomatology and remain poorly described in an Australian population. We hypothesised that the rate of human leukocyte antigen (HLA) DQB1*0602 positivity in the Australian cohort would be comparable to international registries.
Lachlan Stranks, Claire M. Ellender, Keith Wong, Haider Naqvi, Ron Grunstein, Brendon J. Yee, Sheila Sivam   +6 more
wiley   +1 more source

Is obstructive sleep apnea a circadian rhythm disorder?

Journal of Sleep Research, Volume 32, Issue 4, August 2023., 2023
Summary Obstructive sleep apnea is the most common sleep‐related breathing disorder worldwide and remains underdiagnosed. Its multiple associated comorbidities contribute to a decreased quality of life and work performance as well as an increased risk of death.
Julija Šmon, Eva Kočar, Tadeja Pintar, Leja Dolenc‐Grošelj, Damjana Rozman   +4 more
wiley   +1 more source

Solriamfetol improves chronic sleep fragmentation-induced increases in sleep propensity and ameliorates explicit memory in male mice. [PDF]

Sleep, 2023
Obstructive sleep apnea (OSA) is a highly prevalent condition characterized by episodes of partial or complete breath cessation during sleep that induce sleep fragmentation (SF).
Puech C, Badran M, Barrow MB, Runion AR, Gozal D.   +4 more
europepmc   +2 more sources

P003 Randomised, placebo-controlled study of solriamfetol for excessive daytime sleepiness in narcolepsy types 1/2 [PDF]

, 2020
n/
Black, Jed, Carter, Lawrence P, Chen, Dan, Corser, Bruce C, Dauvilliers, Yves, Emsellem, Helene A, Mayer, Geert, Plazzi, Giuseppe, Shapiro, Colin M, Thorpy, Michael J, Wang, Hao   +10 more
core   +1 more source

1269 Off-Label Use of Solriamfetol In Idiopathic Hypersomnia [PDF]

Sleep, 2020
Abstract Introduction Solriamfetol is a new daily dopamine and norepinephrine reuptake inhibitor indicated for improving daytime wakefulness in adults with obstructive sleep apnea (OSA) and narcolepsy. It was FDA-approved on 3/20/2019.
Talha Memon, Tammy Wong
openaire   +1 more source

Science‐Based Approach to Harmonize Contraception Recommendations in Clinical Trials and Pharmaceutical Labels

Clinical Pharmacology &Therapeutics, Volume 113, Issue 2, Page 226-245, February 2023., 2023
This review presents a European Federation of Pharmaceutical Industries and Association/PreClinical Development Expert Group (EFPIA‐PDEG) topic group consensus on a data‐driven approach to harmonized contraception recommendations for clinical trial protocols and product labeling.
Christopher J. Bowman, Nathalie Becourt‐Lhote, Virginie Boulifard, Rüdiger Cordts, Solange Corriol‐Rohou, Brian Enright, Linda Erkman, Jayne Harris, Andreas Hartmann, Jan Hilpert, Sophie Kervyn, Britta Mattson, LaRonda Morford, Mireille Muller, Marcy Powell, Zhanna Sobol, Rajamuthu Srinivasan, Claudia Stark, Kary E. Thompson, Katie J. Turner, Paul Barrow   +20 more
wiley   +1 more source